D-0759-2022 Class II Terminated
FDA drug recall D-0759-2022 was initiated by Pfizer Inc. on Mar 21, 2022 and is designated Class II. Reason for recall: CGMP Deviations: N-nitroso-quinapril and N-nitroso-hydrochlorothiazide impurity above the acceptable daily intake limit. The recall status is terminated (terminated Aug 28, 2024). Affected quantity: 21108 bottles.
Recall Details
- Product Type
- Drugs
- Report Date
- Apr 13, 2022
- Initiation Date
- Mar 21, 2022
- Termination Date
- Aug 28, 2024
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 21108 bottles
Product Description
quinapril HCl/hydrochlorothiazide tablets, 20 mg/12.5 mg*, 90 Tablets bottles, Rx Only, Distributed by: Greenstone, LLC, Peapack, NJ, 07977, Made in Germany, NDC 59762-0220-1
Reason for Recall
CGMP Deviations: N-nitroso-quinapril and N-nitroso-hydrochlorothiazide impurity above the acceptable daily intake limit.
Distribution Pattern
Nationwide
Code Information
Lots DN6931, ED3904 & ED3905; Exp. 03/2023
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0759-2022
- openFDA file date
- Oct 23, 2026
- Loaded by RegDataLab
- Oct 26, 2026